References

3-Iodothyronamine-A thyroid hormone metabolite with distinct target profiles and mode of action

10.1210/er.2018-00182 · 2019 · External reference

Thyroid hormones in diabetes, cancer, and aging

10.1111/acel.13260 · 2020 · External reference

3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone

10.1038/nm1051 · 2004 · External reference

Evolutionary conservation of 3-iodothyronamine as an agonist at the trace amine-associated receptor 1

10.1159/000430839 · 2015 · External reference

New insights into the potential roles of 3-iodothyronamine (T1AM) and newly developed thyronamine-like TAAR1 agonists in neuroprotection

10.3389/fphar.2017.00905 · 2017 · External reference

Delivery of thyronamines (Tams) to the brain: a preliminary study

10.3390/molecules26061616 · 2021 · External reference

Endogenous 3-iodothyronamine (T1Am) and synthetic thyronamine-like analog SG-2 act as novel pleiotropic neuroprotective agents through the modulation of SIRT6

10.3390/molecules25051054 · 2020 · External reference

The 3-iodothyronamine (T1AM) and the 3-iodothyroacetic acid (TA1) indicate a novel connection with the histamine system for neuroprotection

10.1016/j.ejphar.2021.174606 · 2021 · External reference

Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism

10.1111/bph.12697 · 2014 · External reference

Design, synthesis, and evaluation of thyronamine analogues as novel potent mouse trace amine associated receptor 1 (m TAAR1) agonists

10.1021/acs.jmedchem.5b00526 · 2015 · External reference

3-iodothyronamine and derivatives: new allies against metabolic syndrome?

10.3390/ijms21062005 · 2020 · External reference

Thyroid hormone transport proteins

10.1016/s0272-2712(18)30427-x · 1993 · External reference

10.1016/s0021-9258(18)53792-3

10.1016/s0021-9258(18)53792-3 · External reference

Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro- N -acetyl- L -thyronine at 2.2 Å resolution

10.1107/s0907444996003046 · 1996 · External reference

Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy

10.1073/pnas.75.9.4499 · 1978 · External reference

Fibril in senile systemic amyloidosis is derived from normal transthyretin

10.1073/pnas.87.7.2843 · 1990 · External reference

10.1016/j.jmb.2011.12.060

10.1016/j.jmb.2011.12.060 · External reference

Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system

10.1016/j.jacc.2016.06.033 · 2016 · External reference

Transthyretin misfolding, a fatal structural pathogenesis mechanism

2021 · External reference

Inhibiting transthyretin amyloid fibril formation via protein stabilization

10.1073/pnas.93.26.15051 · 1996 · External reference

10.1073/pnas.1121005109

10.1073/pnas.1121005109 · External reference

10.1056/nejmoa1805689

10.1056/nejmoa1805689 · External reference

Tafamidis in hereditary ATTR amyloidosis – our experience on monitoring the ocular manifestations

10.1080/13506129.2016.1236332 · 2016 · External reference

Failure of tafamidis to halt progression of Ala36Pro TTR oculomeningovascular amyloidosis

10.1016/j.jstrokecerebrovasdis.2018.04.033 · 2018 · External reference

10.1002/anie.201608516

10.1002/anie.201608516 · External reference

10.1016/s0022-2836(02)00471-0

10.1016/s0022-2836(02)00471-0 · External reference

10.1021/acs.biochem.8b00642

10.1021/acs.biochem.8b00642 · External reference

10.1093/bioinformatics/btab180

10.1093/bioinformatics/btab180 · External reference

10.1021/bi952501g

10.1021/bi952501g · External reference

10.1021/bi500739q

10.1021/bi500739q · External reference

10.1093/nar/28.1.235

10.1093/nar/28.1.235 · External reference

Identification of transthyretin fibril formation inhibitors using structure-based virtual screening

10.1002/cmdc.201700051 · 2017 · External reference

Unresolved reference

External reference

10.1021/ct400341p

10.1021/ct400341p · External reference

10.1002/jcc.20084

10.1002/jcc.20084 · External reference

10.1002/jcc.24467

10.1002/jcc.24467 · External reference

10.1021/ct300418h

10.1021/ct300418h · External reference

10.1021/bi00151a036

10.1021/bi00151a036 · External reference

Transthyretin Pro 55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement

10.1007/bf00220559 · 1992 · External reference

Genetic aspects of amyloidosis

10.1007/978-1-4684-5958-6_2 · 1991 · External reference

Targeting transthyretin in Alzheimer’s disease: drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer’s disease

10.1016/j.ejmech.2021.113847 · 2021 · External reference

Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis

10.1016/j.bmc.2023.117370 · 2023 · External reference

10.1107/s2052252514021113

10.1107/s2052252514021113 · External reference

10.1016/j.ijms.2004.05.013

10.1016/j.ijms.2004.05.013 · External reference

Transthyretin stabilization: an emerging strategy for the treatment of alzheimer’s disease?

10.3390/ijms21228672 · 2020 · External reference

Diphenyl-methane based thyromimetic inhibitors for transthyretin amyloidosis

2021 · External reference

Identification of a thyroid hormone derivative as a pleiotropic agent for the treatment of Alzheimer’s disease

10.3390/ph14121330 · 2021 · External reference

10.1074/jbc.m115.659912

10.1074/jbc.m115.659912 · External reference

Potential therapeutic applications of thyroid hormone analogs

10.1038/ncpendmet0590 · 2007 · External reference

Thyroid hormone analogues: an update

10.1089/thy.2020.0071 · 2020 · External reference

ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation

10.1074/jbc.m111.275552 · 2012 · External reference

Directional thyroid hormone distribution via the blood stream to target sites

10.1016/j.mce.2017.02.037 · 2017 · External reference